FXR and BET signaling orchestrate to protect β cells
Cayabyab, F.; Tipirneni, J.; Chen, D.; Choi, J.; Hamba, Y.; Pham, N.; Tacto, C.; Wu, J.; Wang, L.; Mirzakhanyan, Y.; Gershon, P. D.; Perez, H.; Harada, N.; Kim, K.; Shaheen, A.; Fang, S.; Ipp, E.; Chen, L.-F.; Wei, Z.; Yoshihara, E.
Show abstract
In both type 1 and type 2 diabetes (T1D and T2D), insulin-producing {beta} cells undergo progressive dysfunction due to inflammation, leading to impaired glucose responsiveness, dedifferentiation, and cell loss. While bile acid (BA) dysregulation under diabetic conditions is known to influence metabolic and inflammatory pathways, its mechanistic role in {beta} cell regulation remains incompletely defined1-3. Here we show that bile acid sensor Farnesoid X receptor (FXR) and Bromodomain and Extra-Terminal motif (BET) signaling cooperatively regulates {beta} cell inflammatory response and {beta} cell identity. We identified the physiological protein-protein interaction between FXR and the bromodomain-containing protein 4 (BRD4) as a regulatory axis that protects against {beta} cell dysfunction. We show that FXR activation by Fexaramine (Fex) together with BRD4 inhibition by JQ1 synergistically suppressed IL-1{beta}-induced inflammation while also improving {beta} cell identity and insulin secretion in both db/db model and high-fat diet (HFD) plus multi low-dose streptozotocin (MLD-STZ) model of diabetes. Importantly, this cooperative effect is abolished in {beta} cell-specific FXR knockout ({beta}FXRKO) mice, establishing that FXR is required for the functional synergy between these pathways in vivo. Mechanistically, structure-guided modeling and mutational analyses identified a direct interaction between FXR and the BD2 domain of BRD4, depending on specific lysine acetylation sites. Additionally, inhibition of the BD2 domain of BET combined with FXR activation markedly improved {beta} cell survival in human T1D and T2D models established from human pluripotent stem cell (hPSC)-derived islet-like organoids (HILOs). Collectively, these findings establish a BA-bromodomain axis as a transcriptional interface linking metabolic signaling and chromatin regulation, and highlight FXR-BET targeting as a promising strategy to counter progressive {beta} cell failure in diabetes.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.